PROJECT 3: The goal of this project is to prepare for a Phase II trial of recombinant ACE2 in human pulmonary arterial hypertension (PAH) patients. ACE2 is a recently discovered peptide which inactivates Angll to make Ang(1- 7);Ang(1-7) signals through the Masi receptor. ACE2 mechanism and consequences are thus distinct from ACE inhibitors and receptor blockers, as neither result in increased Ang(1-7) and Masi signaling. Recombinant ACE2 has already proven effective in blocking or treating established pulmonary arterial hypertension (PAH) in several rodent models, including in Bmpr2-mutation related PAH, and has already passed safety trials in healthy human subjects. Preliminary data suggests that the mechanism by which ACE2 treats PAH is through reversal of cytoskeletal defects common to both idiopathic and heritable PAH, including defects in steroid hormone receptor shuttling, endothelial barrier function, and cell-cell junctions. In HPAH, these defects are a consequence of all classes of BMPR2 mutation, which regulates the cytoskeleton through binding and phosphorylation of key cytoskeletal regulators LIMK1 and TCTEX1;however, these same defects have also been seen in IPAH, and so we hypothesize that they are a common cause of PAH. Because of the demonstrated safety of ACE2 use in healthy humans and the strong mechanistic and efficacy data in multiple mouse models, we think it is prudent and timely to test ACE2 in PAH patients.
In Aim 1, we propose confirming the molecular mechanism by which ACE2 treats PAH.
In Aim 2, we test the safety of ACE2 for prolonged use and withdrawal in mice.
In Aim 3, we carry out a phase lb, single-center, open- label, dose-escalation and multiple dose study to evaluate the safety and early indications of efficacy of rhACE2 in subjects with PAH. At the conclusion of this project, we anticipate preparation for a Phase II trial of ACE2 in human PAH patients.

Public Health Relevance

Recombinant ACE2 is effective in treating multiple animal models of pulmonary arterial hypertension (PAH), by correcting defects in a pathway, cytoskeletal trafficking, not impacted by any existing treatment for PAH. In this study, we complete studies necessary to translate this finding to human patients, including confirmation of mechanism, long term safety studies, and safety and early efficacy studies in PAH patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL108800-03
Application #
8692006
Study Section
Special Emphasis Panel (ZHL1-CSR-Q)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$632,472
Indirect Cost
$209,452
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Chen, Xinping; Talati, Megha; Fessel, Joshua P et al. (2016) Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. Circulation 133:82-97
Evans, Jonathan D W; Girerd, Barbara; Montani, David et al. (2016) BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 4:129-37
Hemnes, Anna R; Zhao, Min; West, James et al. (2016) Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 194:464-75
Talati, Megha H; Brittain, Evan L; Fessel, Joshua P et al. (2016) Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. Am J Respir Crit Care Med 194:719-28
Hay, Bryan R; Pugh, Meredith E; Robbins, Ivan M et al. (2016) Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. Chest 149:660-6
West, James D; Carrier, Erica J; Bloodworth, Nathaniel C et al. (2016) Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One 11:e0148657
Brittain, Evan L; Talati, Megha; Fessel, Joshua P et al. (2016) Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation 133:1936-44
Chung, Wendy K; Austin, Eric D; Best, D Hunter et al. (2015) When to offer genetic testing for pulmonary arterial hypertension. Can J Cardiol 31:544-7
Hemnes, Anna R; Trammell, Aaron W; Archer, Stephen L et al. (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131:401-9; discussion 409
Newman, John H; Brittain, Evan L; Robbins, Ivan M et al. (2015) Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension. Chest 147:1080-5

Showing the most recent 10 out of 37 publications